Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other
disorders, including age-related macular degeneration. Major progress towards a treatment
has been achieved over the past few years, and the first antiangiogenic agents have been
recently approved for use in several countries. Therapeutic angiogenesis (promoting new
vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine,
but further understanding of the mechanisms of vascular morphogenesis is needed first.